Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse vel velit vestibulum, imperdiet tortor vel, suscipit enim. Proin quis ornare nisl. Cras eu mi hendrerit, fermentum sapien eu, finibus eros. Donec felis ante, molestie id mauris sed, tincidunt efficitur massa. Vivamus egestas neque quam, non rhoncus ex mattis a. Aliquam ac lacus varius ipsum volutpat interdum. Sed posuere, purus eget tempor tempor, est sem suscipit magna, a sodales erat libero nec massa. Nunc vitae odio ipsum. Integer porta efficitur elit nec gravida. In auctor metus velit, eu vestibulum tellus convallis ut. Nam eget enim eu magna venenatis viverra vitae sit amet enim.
Phasellus sit amet lectus vel dui egestas tincidunt. Cras in imperdiet urna. Donec commodo diam quis scelerisque luctus. Curabitur ac velit quis est bibendum posuere vel ac mi. Ut tempor, libero sed ornare rhoncus, purus orci laoreet orci, vitae sollicitudin ex sapien non tortor. Morbi eu dictum nisi. Nunc ultricies, lectus vel commodo viverra, orci metus tristique diam, id blandit diam metus vitae turpis. Vestibulum consectetur lectus eu sapien blandit, mollis aliquam diam ultricies. Sed fermentum id ex ac mattis. Donec libero sem, fringilla sit amet volutpat semper, ultricies a tortor. Aenean eu mollis felis. Nam ac orci lorem.
In sapien sem, mollis eu porttitor id, porttitor sed velit. Aenean quis ultricies dui, in posuere enim. In vel diam facilisis, semper mauris quis, vehicula nulla. Maecenas elementum felis sed tellus sagittis egestas. Proin convallis aliquet eleifend. Morbi ac mauris nec felis tincidunt viverra quis eget mi. Nunc vel aliquet mauris. Donec libero justo, scelerisque id mi ut, tempus commodo dui.
Proin laoreet augue et neque eleifend, a consequat dolor tempus. Proin porta quam massa, id iaculis libero elementum vel. Maecenas molestie aliquet velit, nec congue sapien varius a. Morbi quis nibh ex. Aenean vitae purus elementum, luctus elit vel, lacinia erat. Aenean in augue volutpat, gravida arcu quis, sodales augue. Quisque imperdiet pulvinar interdum. Quisque laoreet et mi sit amet convallis. Donec eget sagittis erat.
The RegMed XB Pilot Factory is one of the largest international infrastructures for regenerative medicine. It brings together all the expertise and infrastructure needed to get regenerative medicine to the market. Our mission is to accelerate the development of new solutions to bringing affordable regenerative medicine solutions to patients with chronic disorders while establishing a competitive and sustainable industry.
The Pilot Factory consists of an ecosystem of specialized pilot lines that support universities, research institutes, start-ups and industry with developing, testing, upscaling and producing their new regenerative medicine therapies.
Take a closer look at our state-of-the-art facilities and discover how the RegMed XB Pilot Factory is accelerating the development of regenerative medicine solutions. Watch our video now to learn more!
Why the Regenerative Medicine infrastructure?
The RegMed XB Pilot Factory is an unique infrastructure that consists of facilities covering the entire chain of development and production of stem cells, mini-organs, tissues and smart (bio)materials. Around each pilot line, companies and knowledge institutions work together on the development of (clinical) applications and increasingly better, cheaper, scalable and exportable production equipment and services. The pilot lines are connected and complementary public private partnerships. This has shown to be effective in delivering the highest quality to our clients.
What do we offer?
We offer our infrastructure, state-of-the-art technologies and expertise to universities, research institutes, start-ups and industry.
Strong public-private partnerships.
State-of-the-art technologies and production facilities.
Research and development services and expertise.
Adherence to golden standards and regulatory guidelines.
The current small-scale way we create insulin-producing cells
Biomaterials pilot line
Smart Biomaterials Consortium (SBMC) is the biomaterials pilot line of the Pilot Factory. This pilot line is located in Eindhoven in the vicinity of Eindhoven University and on the Technology Campus.
SBMC has shared development laboratories and a pilot production facility. The development laboratories are the place to optimize the processing and fabrication of biomaterials products, and evaluate its safety, efficacy and biological response. SBMC staff is available to guide the use of equipment and optimization and to carry out contract manufacturing assignments.
In the pilot production facility scale-up and automation challenges for industrial scale fabrication of biomaterials and biodegradable implants can be tackled in an environment representative to your future factories, adhering to all applicable regulations and procedures.
Get in touch with SBMC
This email address is being protected from spambots. You need JavaScript enabled to view it.
NecstGen is the stem cells pilot line of the Pilot Factory with focus on cell and gene therapy. This pilot line is located in Leiden in the vicinity of Leiden Bio Science Park. NecstGen has a purpose-built GMP facility for cell and gene therapy development and manufacturing.
The facility supports researchers and companies in the translation and development of their therapies into the clinical. NecstGen offers process and analytical development, contract manufacturing for cell therapy, gene therapy, viral vectors, as well as cleanroom rental.
NecstGen supports preclinical and clinical grade manufacturing, contract development and production, regulatory dossier support, analytical and process development, industry experts in-house.
LUMC is the iPSC and Organ-on-Chip pilot line of the Pilot Factory. This pilot line is located in Leiden in the vicinity of Leiden Bio Science Park.
The LUMC hiPSC & OoC hotel offers research services to scientists from universities and to companies, supporting them to make human induced pluripotent stem cells (hiPSCs) and Organ-on-Chip (OoC) models.
The hiPSC services contain the isolation and reprogramming of somatic cells and evaluation of hiPSCs. Also, the facility offers the possibility to make isogene (controle) lines with CRISPR/Cas9 technology. The research services on the topic of OoC are related to the biological component rather than the technology itself. Activities include developing protocols and assays, choosing the right chip-setup for specific biological questions and independent qualification.
Innovation Center for Advanced Therapies (ICAT) is the microtissue pilot line of the Pilot Factory. This pilot line is located in Utrecht in the vicinity of Utrecht science park.
ICAT integrates 3 facilities; a biofabrication pilot facility, a GMP simulation facility, and a GMP production facility, enabling the development, optimization and standardization of complex manufacturing processes of engineered immune cells and (patient specific) microtissues.
These facilities are embedded within the environments of an academic medical center with access to a relevant patient population, a clinical trial infrastructure, regulatory expertise.
ReGEN Biomedical is the macrotissue pilot line of the Pilot Factory. This pilot line is located in Maastricht in the vicinity of Brightlands Health Campus.
ReGEN focusses on producing R&D and GMP grade robust and reproducible pieces of tissue on large scale. Applications for these tissues may vary from toxicity or drug screening or ex vivo disease models, to ATMP’s such as allogeneic tissue transplants.
The aim is to develop a fully automated modular production platform, generating regulatory compliant tissue constructs that are aimed to be used in a clinical setting. The platform is designed to be a closed system, equipped with advanced appropriate offline and inline quality control systems, allowing for high throughput production of a wide variety of technology compatible macrotissues.
Do you have questions or do you want to make use of our infrastructure or the expertise of our team, let’s connect. Together we bring regenerative medicine solutions to the patient!
Growth Fund project realizes a national RM-infrastructure consisting of an ecosystem of pilot lines
One of the pillars of the RegMed XB ecosystem initiative is the development of a manufacturing infrastructure. This responds to major challenges in making RM therapies available and affordable to patients, namely the development and industrialization of manufacturing. This is complex (working with living material), must meet high standards (Good Manufacturing Practice) and is currently still labor intensive and not automated. RegMed XB (and its partners) will use Growth Fund resources to realize a national RM infrastructure in the Netherlands, consisting of an ecosystem of pilot lines that support companies and research institutions in developing and valorizing new RM therapies, production technology and production services. Together they cover the entire chain from biomaterials to cells, micro tissues and whole organs, and every possible scale from personalized applications to the development of industrial production. Each link provides both products and services that are directly applicable in (RM) therapies and intermediate or auxiliary products for other steps in the chain.
The RM infrastructure will be built over the next three years after which the operation will be scaled up
Around each pilot line, companies and knowledge institutions work together on further development of (clinical) applications and increasingly better, cheaper, scalable and exportable production equipment and services. With a start in 2021, most of the physical infrastructure will be realized between 2022 and 2024 (in parallel with the required technology platforms). Starting in 2023, the integrated pilot proposition will be open for business as part of the larger ecosystem proposition of RegMed XB. The use of the pilot lines is scaled up between 2025 and 2028 and they generate sufficient revenue after 2028 to cover the costs of operations, maintenance and equipment replacement. Revenue consists of capacity rental, provision of services (expertise, support), provision of education and training, commissioned production, development of production platforms and revenue from spinouts in production equipment and licensing.
This makes it attractive for new and existing companies to become part of the RM infrastructure
Customers/users of the RM infrastructure can make use of all facilities and expertise in the strong ecosystems around each pilot line – around TU/e (SBMC), Leiden Bio Science Park (NecstGen and LUMC), Utrecht Science Park (UMC Utrecht) and Maastricht Health or the Chemelot Campus (ReGEN Biomedical) – and in the broader ecosystem of RegMed XB. In and around the RM infrastructure, a wide range of facilities but also of knowledge / skills will be available: (clinical) validation and valorization, from patent to patient, including hands-on support and funding for startups, assistance in complying with and helping to shape regulations and active involvement of health funds, patient (associations) and insurers. This makes it attractive for new and existing companies from home and abroad to establish themselves at one of the science parks where parts of the RG infrastructure are located and then become/ are part of the RM ecosystem in the Netherlands.
The current small-scale way we create insulin-producing cells
Major challenges in healthcare
The world faces major challenges in health and healthcare. Aging and changing lifestyles are leading to a rapid increase in the number of chronically ill people and those in need of care everywhere. Meanwhile, technological innovation is saving lives, but the downside is that (even) more people are living longer with chronic illness. Our current healthcare system is entirely geared to care for the chronically sick: relieving symptoms and slowing down disease progression. This is expensive and labor-intensive; it is not sustainable in the long term. Capacity shortages are already emerging. The COVID-19 pandemic underscores the scale and urgency of challenges surrounding the overload of our healthcare system.
Regenerative medicine is an opportunity for earning power and health
Regenerative Medicine (RM) focuses on repairing damage to cells, tissues and organs that can prevent or cure chronic diseases. Cells, tissues and (mini-)organs grown outside the body can also be used to diagnose and treat diseases more accurately and more patient-specifically (personalized medicine). Regenerative medicine is the driving force behind the transitions needed to keep our population healthy and our healthcare affordable: from care to cure, from one-size-fits-all to personalization and precision and from reactive to proactive and preventive. The international market potential for regenerative medicine is large and rapidly growing, and the Netherlands has an excellent starting position with an internationally leading knowledge base and an emerging business community in this new sector. A huge opportunity for RM to contribute to the future earning power and health of the Netherlands.
Pilot lines
Innovation Center for Advanced Therapies (ICAT)
Smart BioMaterials Consortium (SBMC)
ReGEN Biomedical
Leiden University Medical Center
Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen)
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse vel velit vestibulum, imperdiet tortor vel, suscipit enim. Proin quis ornare nisl. Cras eu mi hendrerit, fermentum sapien eu, finibus eros. Donec felis ante, molestie id mauris sed, tincidunt efficitur massa. Vivamus egestas neque quam, non rhoncus ex mattis a. Aliquam ac lacus varius ipsum volutpat interdum. Sed posuere, purus eget tempor tempor, est sem suscipit magna, a sodales erat libero nec massa. Nunc vitae odio ipsum. Integer porta efficitur elit nec gravida. In auctor metus velit, eu vestibulum tellus convallis ut. Nam eget enim eu magna venenatis viverra vitae sit amet enim.
Phasellus sit amet lectus vel dui egestas tincidunt. Cras in imperdiet urna. Donec commodo diam quis scelerisque luctus. Curabitur ac velit quis est bibendum posuere vel ac mi. Ut tempor, libero sed ornare rhoncus, purus orci laoreet orci, vitae sollicitudin ex sapien non tortor. Morbi eu dictum nisi. Nunc ultricies, lectus vel commodo viverra, orci metus tristique diam, id blandit diam metus vitae turpis. Vestibulum consectetur lectus eu sapien blandit, mollis aliquam diam ultricies. Sed fermentum id ex ac mattis. Donec libero sem, fringilla sit amet volutpat semper, ultricies a tortor. Aenean eu mollis felis. Nam ac orci lorem.
In sapien sem, mollis eu porttitor id, porttitor sed velit. Aenean quis ultricies dui, in posuere enim. In vel diam facilisis, semper mauris quis, vehicula nulla. Maecenas elementum felis sed tellus sagittis egestas. Proin convallis aliquet eleifend. Morbi ac mauris nec felis tincidunt viverra quis eget mi. Nunc vel aliquet mauris. Donec libero justo, scelerisque id mi ut, tempus commodo dui.
Proin laoreet augue et neque eleifend, a consequat dolor tempus. Proin porta quam massa, id iaculis libero elementum vel. Maecenas molestie aliquet velit, nec congue sapien varius a. Morbi quis nibh ex. Aenean vitae purus elementum, luctus elit vel, lacinia erat. Aenean in augue volutpat, gravida arcu quis, sodales augue. Quisque imperdiet pulvinar interdum. Quisque laoreet et mi sit amet convallis. Donec eget sagittis erat.
At RegMed XB, we empower researchers to translate their scientific discoveries into real-world applications. Whether it's through guiding academic projects or supporting the creation of spinoff companies, we provide the tools, resources, and expertise to bring innovation in regenerative medicine closer to the market.
Turn your research into real-world impact
Translating breakthrough research into practical solutions can be challenging, and sometimes, establishing a spinoff is a crucial next step. We’re here to help with expert advice, access to our extensive network, and financial support through innovation vouchers. Our Valorization Services are designed to assist you at every stage of the journey—from assessing the potential of your startup idea to helping you navigate the complexities of the regenerative medicine market.
RegMed XB, in partnership with the Dutch CardioVascular Alliance (DCVA) and the F!RST fund, operates the Thematic Technology Transfer (TTT) program. This program provides funding specifically for academic projects with high valorization potential, offering the financial boost you need to push your innovation forward.
Our in-kind support is subsidized and free of charge for researchers from all universities in the Netherlands, not just our consortium partners. This complements the work of Technology Transfer Offices (TTOs) by offering deeper expertise in the niche market of regenerative medicine.
Why work with RegMed XB?
Our deep knowledge and experience in evaluating and setting up startups make us the ideal partner for ambitious researchers looking to bring their innovations to market. Supporting translation-driven projects in the field of regenerative medicine aligns perfectly with our overarching mission to achieve significant breakthroughs for patient care.
How we can help
Expert Guidance: Our team offers tailored advice and strategic support for your translation efforts.
Financial Support: We provide access to innovation vouchers to help fund your project.
Network Access: Leverage our vast network of experts, investors, and institutions to accelerate your research’s impact.
Ready to take the next step?
If you’re ready to explore how RegMed XB can support your project—whether it’s learning more about our innovation vouchers, advice on setting up a startup, or simply discovering how we can collaborate—get in touch with us.
